What is IBRX's current stock price?

IBRX (ImmunityBio, Inc.) is currently trading at $7.22 with a market cap of $7.56B.

What sector is ImmunityBio, Inc. in?

ImmunityBio, Inc. (IBRX) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is IBRX a good stock to buy?

Analysts have a Buy consensus on IBRX with a price target of $13.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

IBRX ImmunityBio, Inc.

Healthcare

$7.22-6.72%ClosedMarket Cap: $7.56B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-8.52

P/S

53.64

EV/EBITDA

-44.23

DCF Value

$-22.44

FCF Yield

-4.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

93.8%

Operating Margin

-185.4%

Net Margin

-606.2%

ROE

138.7%

ROA

-132.2%

ROIC

-44.5%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$44.2M	$-632.8M	$—
Q4 null	$38.3M	$-61.9M	$—
FY null	$113.3M	$-351.4M	$—
Q3 null	$32.1M	$-67.3M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$13.00

Target (Median)

$12.00

Target Range

$12.00 - $15.00

1 Strong Buy4 Buy0 Hold0 Sell0 Strong Sell

BTIGBuy

2026-05-21

HC Wainwright & Co.Buy

2026-05-20

D. Boral CapitalBuy

2026-05-05

D. Boral CapitalBuy

2026-03-26

Piper SandlerOverweight

2026-03-04

Trading Activity

Insider Trades

View All

SOON-SHIONG PATRICKdirector, 10 percent owner, officer: See remarks

SellThu Apr 02

SOON-SHIONG PATRICKdirector, 10 percent owner, officer: See remarks

SellThu Apr 02

Simon Barry J.director

SellThu Feb 26

SOON-SHIONG PATRICKdirector, 10 percent owner, officer: See remarks

SellTue Feb 24

SOON-SHIONG PATRICKdirector, 10 percent owner, officer: See remarks

SellTue Feb 24

Latest News

ImmunityBio 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against ImmunityBio, Inc. - IBRXBusiness Wire · Fri May 22

INVESTOR DEADLINE TUESDAY: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - RGRD LawPRNewsWire · Thu May 21

IBRX 6-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims -- Hagens BermanNewsfile Corp · Wed May 20

IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26thGlobeNewsWire · Mon May 18

INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - RGRD LawGlobeNewsWire · Wed May 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.07

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

Peers